© 2020 MJH Life Sciences and Drug Topics. All rights reserved.
June 29, 2020
A new computer algorithm might be the next step toward accurate prediction of adverse drug reactions.
June 26, 2020
Officials with the FDA approved fenfluramine (Fintepla, Zogenix) oral solution, CIV for the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older.
June 23, 2020
The first and only one of its kind, metoclopramide nasal spray offers relief to often debilitating symptoms of the gastrointestinal disease.
June 22, 2020
On February 27, 2020, the FDA approved an intravenous solution of amisulpride (Barhemsys; Acacia Pharma) to treat and prevent postoperative nausea and vomiting.
June 17, 2020
EndeavorRx (Akili Interactive), a prescription-only game-based device, is indicated for use in children ages 8 to 12 years old with primarily inattentive or combined-type ADHD who have demonstrated an attention issue.
FDA approval for the secukinumab (Cosentyx, Novartis) for non-radiographic axial spondyloarthritis was based on results from the PREVENT trial, which showed significant reduction in disease activity.
June 15, 2020
Abbott’s FreeStyle Libre 2 is an integrated continuous glucose monitoring system for adults and children ages 4 and older with diabetes.
June 12, 2020
Officials with the FDA have approved dolutegravir (Tivicay PD, ViiV Healthcare) dispersible tablets for oral suspension for children who are at least 4 weeks of age and weigh at least 3 kg.
June 08, 2020
Officials with the FDA have approved imipenem, cilastatin, and relebactam (Recarbrio, Merck) for the treatment of adults with hospital-acquired and ventilator-associated bacterial pneumonia.
June 03, 2020
Ixekizumab (Taltz, Eli Lilly) is the first interleukin-17A antagonist to be approved for non-radiographic axial spondyloarthritis.